ALGOMEDIX, INC.

Algomedix is an emerging biotechnology company which is using the advances in precision medicine to accelerate drug discovery and development for TRP (Transient Receptor Potential) targeted therapeutics. Critical members of the large TRP superfamily include TRPA1, which is a validated target recognized by the pharmaceutical industry for the discovery and development of novel therapeutics to treat pain, inflammation, ocular and dermatological disease. Algomedix has successfully identified novel small molecules that target human TRPA1 with both high potency and specificity, and have been optimized to have excellent drug-like properties. Thus, the Algomedix compounds represent a major advance in next-generation pain killers which have no opioid related, NSAID related, or gabapentanoid adverse effects, and have been rationally designed to have no addiction or abuse liabilities. These advantages are further enhanced by a primary peripheral mechanism of action, blocking pain at its source. Algomedix possesses near-term clinical development opportunities combined with novel approaches to developing its first-in-class novel therapeutics addressing a critical unmet medical need. Algomedix's most advanced patented compound is in late-stage preclinical development and prepared to advance to clinical trials. This compound has demonstrated potent analgesic activity activity in multiple established pain models, which are recognized as the gold standards in the areas of osteoarthritis pain (OA), neuropathic pain, and chemotherapeutic-induced peripheral neuropathy. Due to the critical and fundamental role of TRPA1 in mediating the initial steps of pain signaling throughout the body, there are multiple therapeutic applications for treating chronic and acute pain in patients. In addition, Algomedix is pursuing programs developing a pipeline of novel, first-in-class molecules for other indications, which include chronic kidney disease and cardiac hypertrophy